The next debate on embryo science
By Editorial,
Nature Biotechnology
| 08. 02. 2021
The International Society for Stem Cell Research has called for broad public dialogue on the ethics of human embryo research beyond 14 days post-fertilization. National jurisdictions should seize the moment.
A longstanding prohibition against culturing human embryos for more than 14 days is now open for discussion, according to revised research guidelines released in May by the International Society for Stem Cell Research (ISSCR). The society’s change in position was prompted by recent advances in embryo culture methods that promise to deepen understanding of human development at the stage when the embryo implants in the uterus—knowledge that may lead to new therapies for infertility and miscarriage. The ISSCR is to be commended for encouraging ethical reflection on extending the 14-day rule before the world is caught off guard by an embryo experiment that goes beyond the accepted time frame. It is now up to interested parties in national scientific, political, ethics and religious communities to take up the ISSCR’s challenge.
In 1978, the birth of the first baby created through in vitro fertilization (IVF) was met with a storm of controversy. IVF provoked deep concerns and anxieties about the wisdom of tampering with the natural order of reproduction. Once human procreation was unlinked from coitus, impossible things became possible: women...
Related Articles
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...